HRP20211542T1 - Tetrasupstituirani spojevi alkena i njihova uporaba - Google Patents
Tetrasupstituirani spojevi alkena i njihova uporaba Download PDFInfo
- Publication number
- HRP20211542T1 HRP20211542T1 HRP20211542TT HRP20211542T HRP20211542T1 HR P20211542 T1 HRP20211542 T1 HR P20211542T1 HR P20211542T T HRP20211542T T HR P20211542TT HR P20211542 T HRP20211542 T HR P20211542T HR P20211542 T1 HRP20211542 T1 HR P20211542T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- amino
- indazol
- phenoxy
- enamide
- Prior art date
Links
- -1 alkene compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- XZJFHURTQYQLNS-YTWISQNBSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-(4-propan-2-ylphenyl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=C(C=C1)C(C)C)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 XZJFHURTQYQLNS-YTWISQNBSA-N 0.000 claims 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical group FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical group FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 claims 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- XKQXNEMJPLKCQY-NVVIBEMGSA-N (E)-1-(azetidin-1-yl)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]but-2-en-1-one Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N2CCC2)C=C1 XKQXNEMJPLKCQY-NVVIBEMGSA-N 0.000 claims 1
- IWMASTXZSVQICA-UFGVEBAKSA-N (E)-1-(azetidin-1-yl)-4-[2-[4-[(E)-2-cyclobutyl-1-(1H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]but-2-en-1-one Chemical compound N1(CCC1)C(\C=C\CNCCOC1=CC=C(C=C1)/C(=C(\C1=CC=CC=C1)/C1CCC1)/C=1C=C2C=NNC2=CC=1)=O IWMASTXZSVQICA-UFGVEBAKSA-N 0.000 claims 1
- VVSBTYVFECYCQP-GGGNVPQESA-N (E)-1-(azetidin-1-yl)-4-[2-[4-[(E)-2-cyclobutyl-1-(3-fluoro-2H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]but-2-en-1-one Chemical compound N1(CCC1)C(\C=C\CNCCOC1=CC=C(C=C1)/C(=C(\C1=CC=CC=C1)/C1CCC1)/C=1C=C2C(=NNC2=CC=1)F)=O VVSBTYVFECYCQP-GGGNVPQESA-N 0.000 claims 1
- QNKAHXVYIGGUNI-LXRIAEJXSA-N (E)-4-[1-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]propan-2-ylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCC(C)NC/C=C/C(=O)N(C)C)C=C1 QNKAHXVYIGGUNI-LXRIAEJXSA-N 0.000 claims 1
- SGTRZXMLQWMIHH-GZMTYSCESA-N (E)-4-[2-[2-fluoro-4-[(Z)-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=C(OCCNC/C=C/C(=O)N(C)C)C=CC(=C1)\C(=C(\CC)/C1=CC=CC=C1)\C=1C=C2C(=NNC2=CC=1)F SGTRZXMLQWMIHH-GZMTYSCESA-N 0.000 claims 1
- ZWCLUVRWORBUCI-GZMTYSCESA-N (E)-4-[2-[3-fluoro-4-[(Z)-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC=1C=C(OCCNC/C=C/C(=O)N(C)C)C=CC=1\C(=C(\CC)/C1=CC=CC=C1)\C=1C=C2C(=NNC2=CC=1)F ZWCLUVRWORBUCI-GZMTYSCESA-N 0.000 claims 1
- BYAUIDXIQATDBT-XWSKKVMVSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-(2,3,4,5,6-pentadeuteriophenyl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=C(C(=C(C(=C1[2H])[2H])[2H])[2H])[2H])\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 BYAUIDXIQATDBT-XWSKKVMVSA-N 0.000 claims 1
- IJSAVBFRPBCXEM-UNPIIDSUSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-(2-methylphenyl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=C(C=CC=C1)C)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 IJSAVBFRPBCXEM-UNPIIDSUSA-N 0.000 claims 1
- KOPRKPFZJZHQEO-PXBKXDIXSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-(2-propan-2-ylphenyl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=C(C=CC=C1)C(C)C)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 KOPRKPFZJZHQEO-PXBKXDIXSA-N 0.000 claims 1
- GSFPMECDVDDAFK-OXNICXHZSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-[2-(trifluoromethoxy)phenyl]but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=C(C=CC=C1)OC(F)(F)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 GSFPMECDVDDAFK-OXNICXHZSA-N 0.000 claims 1
- HMHAOOGAQWOESE-WZRICASNSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-1-morpholin-4-ylbut-2-en-1-one Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N2CCOCC2)C=C1 HMHAOOGAQWOESE-WZRICASNSA-N 0.000 claims 1
- SKBGANMCFDZJGD-CXVYSGNSSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-1-piperidin-1-ylbut-2-en-1-one Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N2CCCCC2)C=C1 SKBGANMCFDZJGD-CXVYSGNSSA-N 0.000 claims 1
- ONJRAFMPNSBPEE-LRPCBACBSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-1-pyrrolidin-1-ylbut-2-en-1-one Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N2CCCC2)C=C1 ONJRAFMPNSBPEE-LRPCBACBSA-N 0.000 claims 1
- JGZMLEZRYJFWFI-RXDFFFNUSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N,3-trimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C(=C/C(=O)N(C)C)/C)C=C1 JGZMLEZRYJFWFI-RXDFFFNUSA-N 0.000 claims 1
- BYAUIDXIQATDBT-GIHLFXONSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 BYAUIDXIQATDBT-GIHLFXONSA-N 0.000 claims 1
- KNIRULCTYAPZGF-WFALJASRSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N-methyl-N-prop-2-ynylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(CC#C)C)C=C1 KNIRULCTYAPZGF-WFALJASRSA-N 0.000 claims 1
- IHWWMNLPEGDQKH-WFALJASRSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N-methyl-N-propylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(CCC)C)C=C1 IHWWMNLPEGDQKH-WFALJASRSA-N 0.000 claims 1
- WCMKZAWIDVVVGZ-LXRIAEJXSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]propylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OC(CNC/C=C/C(=O)N(C)C)C)C=C1 WCMKZAWIDVVVGZ-LXRIAEJXSA-N 0.000 claims 1
- SHMCPIBYNRTIND-KNYVZUDDSA-N (E)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylprop-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/C)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 SHMCPIBYNRTIND-KNYVZUDDSA-N 0.000 claims 1
- ZVSFNEPLVBUNSI-BBMPZIBOSA-N (E)-4-[2-[4-[(E)-1-(3,6-difluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC(=C(C=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)F ZVSFNEPLVBUNSI-BBMPZIBOSA-N 0.000 claims 1
- PISNIAALHCUNMD-GPPDWVJXSA-N (E)-4-[2-[4-[(E)-1-(3,7-difluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=C(C=C(C=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)F PISNIAALHCUNMD-GPPDWVJXSA-N 0.000 claims 1
- LEXZTCXGVKMFPN-BTAVWWDFSA-N (E)-4-[2-[4-[(E)-1-(3-fluoro-2H-indazol-5-yl)-2-(2-fluorophenyl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)\C(=C(/CC)\C1=C(C=CC=C1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 LEXZTCXGVKMFPN-BTAVWWDFSA-N 0.000 claims 1
- PMGMQWBSVHCGIQ-NGCJCMEMSA-N (E)-4-[2-[4-[(E)-1-(3-fluoro-2H-indazol-5-yl)-2-(3-fluorophenyl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)\C(=C(/CC)\C1=CC(=CC=C1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 PMGMQWBSVHCGIQ-NGCJCMEMSA-N 0.000 claims 1
- VDFSTKJDNQBQNK-NLJKXMAYSA-N (E)-4-[2-[4-[(E)-1-(3-fluoro-2H-indazol-5-yl)-2-[3-fluoro-5-(trifluoromethyl)phenyl]but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)\C(=C(/CC)\C1=CC(=CC(=C1)C(F)(F)F)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 VDFSTKJDNQBQNK-NLJKXMAYSA-N 0.000 claims 1
- HJFBOGYCSGBAHP-BBCYJOBVSA-N (E)-4-[2-[4-[(E)-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 HJFBOGYCSGBAHP-BBCYJOBVSA-N 0.000 claims 1
- CELHJEWHLAEJLQ-SCEWWSSDSA-N (E)-4-[2-[4-[(E)-1-(3-fluoro-2H-indazol-5-yl)-2-phenylpent-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)\C(=C(/CCC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 CELHJEWHLAEJLQ-SCEWWSSDSA-N 0.000 claims 1
- OWBKOVQQBYPWMV-NHSHXRLWSA-N (E)-4-[2-[4-[(E)-1-(3-fluoro-2H-indazol-5-yl)-3-methyl-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)\C(=C(/C(C)C)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 OWBKOVQQBYPWMV-NHSHXRLWSA-N 0.000 claims 1
- MWFZLTHOKKDOCF-KUHISYQZSA-N (E)-4-[2-[4-[(E)-1-(4-fluoro-1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=C2C=NNC2=CC=C1\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 MWFZLTHOKKDOCF-KUHISYQZSA-N 0.000 claims 1
- DZMJHHAIBHJATA-FBXKWOBBSA-N (E)-4-[2-[4-[(E)-1-(7-fluoro-1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC=1C=C(C=C2C=NNC=12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1 DZMJHHAIBHJATA-FBXKWOBBSA-N 0.000 claims 1
- XTOBEVKGYPUREG-FQGFXNDRSA-N (E)-4-[2-[4-[(E)-2-(2,4-difluorophenyl)-1-(3-fluoro-2H-indazol-5-yl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=C(C=CC(=C1)F)/C(=C(/C=1C=C2C(=NNC2=CC=1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)/CC XTOBEVKGYPUREG-FQGFXNDRSA-N 0.000 claims 1
- ABHISGKEAONFFH-FQGFXNDRSA-N (E)-4-[2-[4-[(E)-2-(2,5-difluorophenyl)-1-(3-fluoro-2H-indazol-5-yl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=C(C=C(C=C1)F)/C(=C(/C=1C=C2C(=NNC2=CC=1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)/CC ABHISGKEAONFFH-FQGFXNDRSA-N 0.000 claims 1
- UAGIGRSAJJPKNK-SWJDANAMSA-N (E)-4-[2-[4-[(E)-2-(2,6-difluorophenyl)-1-(3-fluoro-2H-indazol-5-yl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=C(C(=CC=C1)F)/C(=C(/C=1C=C2C(=NNC2=CC=1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)/CC UAGIGRSAJJPKNK-SWJDANAMSA-N 0.000 claims 1
- JPUFWNHNRWVQOB-LRCCUPQMSA-N (E)-4-[2-[4-[(E)-2-(2-chloro-4-fluorophenyl)-4,4,4-trifluoro-1-(3-fluoro-2H-indazol-5-yl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound ClC1=C(C=CC(=C1)F)/C(=C(/C=1C=C2C(=NNC2=CC=1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)/CC(F)(F)F JPUFWNHNRWVQOB-LRCCUPQMSA-N 0.000 claims 1
- CPJWBFRSMBEZCK-XDCZQARBSA-N (E)-4-[2-[4-[(E)-2-(2-ethylphenyl)-1-(1H-indazol-5-yl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound C(C)C1=C(C=CC=C1)/C(=C(/C=1C=C2C=NNC2=CC=1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)/CC CPJWBFRSMBEZCK-XDCZQARBSA-N 0.000 claims 1
- OTHJCRCZLXVTJC-OXNICXHZSA-N (E)-4-[2-[4-[(E)-2-[2-(difluoromethoxy)phenyl]-1-(1H-indazol-5-yl)but-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC(OC1=C(C=CC=C1)/C(=C(/C=1C=C2C=NNC2=CC=1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)/CC)F OTHJCRCZLXVTJC-OXNICXHZSA-N 0.000 claims 1
- FTVNWWZHNAEODZ-NPCMFBQISA-N (E)-4-[2-[4-[(E)-2-cyclobutyl-1-(1H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]-1-morpholin-4-ylbut-2-en-1-one Chemical compound C1(CCC1)\C(=C(/C=1C=C2C=NNC2=CC=1)\C1=CC=C(OCCNC/C=C/C(=O)N2CCOCC2)C=C1)\C1=CC=CC=C1 FTVNWWZHNAEODZ-NPCMFBQISA-N 0.000 claims 1
- NGZJKELZGBIWKS-ILJVEFDVSA-N (E)-4-[2-[4-[(E)-2-cyclobutyl-1-(1H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound C1(CCC1)\C(=C(/C=1C=C2C=NNC2=CC=1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)\C1=CC=CC=C1 NGZJKELZGBIWKS-ILJVEFDVSA-N 0.000 claims 1
- INOYYRBDACUQLQ-SDHJFJMISA-N (E)-4-[2-[4-[(E)-2-cyclobutyl-1-(1H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]-N-(2-hydroxyethyl)-N-methylbut-2-enamide Chemical compound C1(CCC1)\C(=C(/C=1C=C2C=NNC2=CC=1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)CCO)C=C1)\C1=CC=CC=C1 INOYYRBDACUQLQ-SDHJFJMISA-N 0.000 claims 1
- RZKAJBCSUKYTJH-MHLZQRODSA-N (E)-4-[2-[4-[(E)-2-cyclobutyl-1-(3-fluoro-2H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN(C)C(=O)\C=C\CNCCOc1ccc(cc1)C(=C(\C1CCC1)c1ccccc1)\c1ccc2n[nH]c(F)c2c1 RZKAJBCSUKYTJH-MHLZQRODSA-N 0.000 claims 1
- MDQBYNZQZSIGCX-UHXYOKQCSA-N (E)-4-[2-[4-[(E)-2-cyclobutyl-1-(3-fluoro-2H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]-N-(2-hydroxyethyl)-N-methylbut-2-enamide Chemical compound C1(CCC1)\C(=C(/C=1C=C2C(=NNC2=CC=1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)CCO)C=C1)\C1=CC=CC=C1 MDQBYNZQZSIGCX-UHXYOKQCSA-N 0.000 claims 1
- ANPKCECOJASIIW-IDDGTSSNSA-N (E)-4-[2-[4-[(E)-2-cyclobutyl-1-(4-fluoro-1H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound C1(CCC1)\C(=C(/C=1C(=C2C=NNC2=CC=1)F)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)\C1=CC=CC=C1 ANPKCECOJASIIW-IDDGTSSNSA-N 0.000 claims 1
- AJBHTGXHFSFGDF-MKGSNTHKSA-N (E)-4-[2-[4-[(E)-2-cyclopropyl-1-(1H-indazol-5-yl)-2-phenylethenyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound C1(CC1)\C(=C(/C=1C=C2C=NNC2=CC=1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)\C1=CC=CC=C1 AJBHTGXHFSFGDF-MKGSNTHKSA-N 0.000 claims 1
- NKUTWTMFNLILMP-QJBWQZNKSA-N (E)-4-[2-[4-[(E)-4-chloro-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylbut-2-enamide Chemical compound ClCC\C(=C(/C=1C=C2C=NNC2=CC=1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)C)C=C1)\C1=CC=CC=C1 NKUTWTMFNLILMP-QJBWQZNKSA-N 0.000 claims 1
- HDZPSTWNWNQCKL-QXKICNMKSA-N (E)-4-[2-[5-[(Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]pyridin-2-yl]oxyethylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)/C(=C(\CC)/C1=CC=CC=C1)/C=1C=CC(=NC=1)OCCNC/C=C/C(=O)N(C)C HDZPSTWNWNQCKL-QXKICNMKSA-N 0.000 claims 1
- CHTADNOUBDQPGY-LIVMYXSUSA-N (E)-4-[2-[5-[(Z)-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]pyridin-2-yl]oxyethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)/C(=C(\CC)/C1=CC=CC=C1)/C=1C=CC(=NC=1)OCCNC/C=C/C(=O)N(C)C CHTADNOUBDQPGY-LIVMYXSUSA-N 0.000 claims 1
- AMCJZBVFOMHXET-UIEUVHGMSA-N (E)-4-[2-[5-[(Z)-2-(2-chloro-4-fluorophenyl)-1-(3-fluoro-2H-indazol-5-yl)but-1-enyl]pyridin-2-yl]oxyethylamino]-N,N-dimethylbut-2-enamide Chemical compound ClC1=C(C=CC(=C1)F)\C(=C(\C=1C=C2C(=NNC2=CC=1)F)/C=1C=CC(=NC=1)OCCNC/C=C/C(=O)N(C)C)\CC AMCJZBVFOMHXET-UIEUVHGMSA-N 0.000 claims 1
- GRBZOOPGDIOSRI-DNFMFZRLSA-N (E)-4-[2-[5-[(Z)-2-(2-chloro-4-fluorophenyl)-4,4,4-trifluoro-1-(3-fluoro-2H-indazol-5-yl)but-1-enyl]pyridin-2-yl]oxyethylamino]-N,N-dimethylbut-2-enamide Chemical compound ClC1=C(C=CC(=C1)F)\C(=C(\C=1C=C2C(=NNC2=CC=1)F)/C=1C=CC(=NC=1)OCCNC/C=C/C(=O)N(C)C)\CC(F)(F)F GRBZOOPGDIOSRI-DNFMFZRLSA-N 0.000 claims 1
- VTKJYVHHEZSKIU-VEUIJQNLSA-N (E)-4-[2-[5-[(Z)-2-cyclobutyl-1-(3-fluoro-2H-indazol-5-yl)-2-phenylethenyl]pyridin-2-yl]oxyethylamino]-N,N-dimethylbut-2-enamide Chemical compound C1(CCC1)/C(=C(\C=1C=C2C(=NNC2=CC=1)F)/C=1C=CC(=NC=1)OCCNC/C=C/C(=O)N(C)C)/C1=CC=CC=C1 VTKJYVHHEZSKIU-VEUIJQNLSA-N 0.000 claims 1
- UPQYISDFYSHYPK-LIVMYXSUSA-N (E)-4-[2-[6-[(Z)-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]pyridin-3-yl]oxyethylamino]-N,N-dimethylbut-2-enamide Chemical compound FC1=NNC2=CC=C(C=C12)/C(=C(\CC)/C1=CC=CC=C1)/C1=CC=C(C=N1)OCCNC/C=C/C(=O)N(C)C UPQYISDFYSHYPK-LIVMYXSUSA-N 0.000 claims 1
- HTANCVOGPRANAG-ZIPLWCFLSA-N (E)-4-[3-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]butan-2-ylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OC(C(C)NC/C=C/C(=O)N(C)C)C)C=C1 HTANCVOGPRANAG-ZIPLWCFLSA-N 0.000 claims 1
- WPOXXYZECKZYIU-COBOLPIMSA-N (E)-4-[3-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]propylamino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCCNC/C=C/C(=O)N(C)C)C=C1 WPOXXYZECKZYIU-COBOLPIMSA-N 0.000 claims 1
- QZKUFIBTIUXALC-NEWFTZRXSA-N (E)-4-[[1-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]-2-methylpropan-2-yl]amino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCC(C)(C)NC/C=C/C(=O)N(C)C)C=C1 QZKUFIBTIUXALC-NEWFTZRXSA-N 0.000 claims 1
- IPWJTFIXMIANAS-NEWFTZRXSA-N (E)-4-[[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]-2-methylpropyl]amino]-N,N-dimethylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OC(CNC/C=C/C(=O)N(C)C)(C)C)C=C1 IPWJTFIXMIANAS-NEWFTZRXSA-N 0.000 claims 1
- LFEZYIHPMLRGKD-XCAXPPOQSA-N (E)-5-[2-[4-[(E)-4-fluoro-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N,N-dimethylpent-2-enamide Chemical compound FCC\C(=C(/C=1C=C2C(=NNC2=CC=1)F)\C1=CC=C(OCCNCC/C=C/C(=O)N(C)C)C=C1)\C1=CC=CC=C1 LFEZYIHPMLRGKD-XCAXPPOQSA-N 0.000 claims 1
- STJCSULDLUUSDZ-RFRFRYNVSA-N (E)-N,N-dimethyl-4-[2-[4-[(E)-4,4,4-trifluoro-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]but-2-enamide Chemical compound CN(C(\C=C\CNCCOC1=CC=C(C=C1)/C(=C(/CC(F)(F)F)\C1=CC=CC=C1)/C=1C=C2C(=NNC2=CC=1)F)=O)C STJCSULDLUUSDZ-RFRFRYNVSA-N 0.000 claims 1
- JPFTZIJTXCHJNE-HMOQVRKWSA-N (E)-N,N-dimethyl-4-[2-[5-[(Z)-4,4,4-trifluoro-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]pyridin-2-yl]oxyethylamino]but-2-enamide Chemical compound CN(C(\C=C\CNCCOC1=NC=C(C=C1)\C(=C(\CC(F)(F)F)/C1=CC=CC=C1)\C=1C=C2C(=NNC2=CC=1)F)=O)C JPFTZIJTXCHJNE-HMOQVRKWSA-N 0.000 claims 1
- CJRQBWXFQCEJCX-QYBKERMPSA-N (E)-N-(2-hydroxyethyl)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-(2-methylphenyl)but-1-enyl]phenoxy]ethylamino]-N-methylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=C(C=CC=C1)C)\C1=CC=C(OCCNC/C=C/C(=O)N(C)CCO)C=C1 CJRQBWXFQCEJCX-QYBKERMPSA-N 0.000 claims 1
- QIWHVMAUSVRALX-SOWMIHEKSA-N (E)-N-(2-hydroxyethyl)-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N-methylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)CCO)C=C1 QIWHVMAUSVRALX-SOWMIHEKSA-N 0.000 claims 1
- RYADJHUJVMLDOM-LOPCMPRHSA-N (E)-N-but-3-ynyl-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N-methylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)CCC#C)C=C1 RYADJHUJVMLDOM-LOPCMPRHSA-N 0.000 claims 1
- QOMBARXKUXTPOS-LXRIAEJXSA-N (E)-N-ethyl-4-[2-[4-[(E)-1-(1H-indazol-5-yl)-2-phenylbut-1-enyl]phenoxy]ethylamino]-N-methylbut-2-enamide Chemical compound N1N=CC2=CC(=CC=C12)\C(=C(/CC)\C1=CC=CC=C1)\C1=CC=C(OCCNC/C=C/C(=O)N(C)CC)C=C1 QOMBARXKUXTPOS-LXRIAEJXSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 101710196141 Estrogen receptor Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
- C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (26)
1. Spoj prikazan formulom II:
[image]
naznačen time što:
Ri je odabran iz skupine koju čine metil, etil, ciklobutil, ciklopropil, propil, izopropil, -CH2CF3, -CH2CH2F, i -CH2CH2Cl;
R2 je odabran iz skupine koju čine H i F;
n je 0-1;
R3 je F kada n=1;
m je 0-2;
R4 su isti ili različiti i neovisno su odabrani iz skupine koju čine F, CF3, Cl, izopropil, -OCH3, -OCHF2, -OCF3, etil i metil;
p je 0-1;
R5 je F kada p=1;
R6 i R7 su isti ili različiti i neovisno su odabrani iz skupine koju čine metil, etil, propil, -CH2CH2OH i
[image]
pri čemu r je 1 ili 2; ili, pri čemu R6 i R7 tvore 4-6 člani heterociklički prsten s N na koji su oni vezani, pri čemu navedeni heterociklički prsten po izboru sadrži kisikov atom, i pri čemu je navedeni heterociklički prsten po izboru supstituiran s F, ili -CH2F;
Rs je odabran iz skupine koju čine H i -CH3;
i R13, R14, R15, i R16 su neovisno odabrani iz skupine koju čine -H ili -CH3;
ili njegove farmaceutski prihvatljive soli.
2. Spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 1, prikazan formulom I:
[image]
naznačen time što:
Ri je odabran iz skupine koju čine metil, etil, ciklobutil, ciklopropil i -CH2CH2Cl;
R2 je odabran iz skupine koju čine H i F;
n je 0-1;
R3 je F kada n=1;
m je 0-2;
R4 su isti ili različiti i neovisno su odabrani iz skupine koju čine F, CF3, Cl, izopropil, -OCH3, -OCHF2, -OCF3, etil i metil;
p je 0-1;
R5 je F kada p=1;
R6 i R7 su isti ili različiti i neovisno su odabrani iz skupine koju čine metil, etil, propil, -CH2CH2OH i
[image]
pri čemu r je 1 ili 2; ili, pri čemu R6 i R7 tvore 4-6 člani heterociklički prsten s N na koji su oni vezani, pri čemu navedeni heterociklički prsten po izboru sadrži kisikov atom, i pri čemu je navedeni heterociklički prsten po izboru supstituiran s F, ili -CH2F;
R8 je odabran iz skupine koju čine H i CH3;
ili njegove farmaceutski prihvatljive soli.
3. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što R1 je etil ili ciklobutil.
4. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što R6 i R7 su oba metil, i pri čemu R8 je H.
5. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što R2 je F.
6. Spoj prema jednom od patentnih zahtjeva 1-4,
pri čemu m je 2, i jedan od R4 je F i drugi R4 je Cl; ili
pri čemu m je 2 i oba R4 su F; ili
pri čemu m je 0.
7. Spoj prema jednom od patentnih zahtjeva 1-4, naznačen time što n je 1 i R3 je F; ili pri čemu n je 0.
8. Spoj prema jednom od patentnih zahtjeva 1-4, naznačen time što p je 1 i R5 je F; ili pri čemu p je 0.
9. Spoj prema patentnom zahtjevu 1 ili zahtjevu 2 naznačen time što ima slijedeću formulu:
[image]
ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 1 naznačen time što ima slijedeću formulu:
[image]
ili njegova farmaceutski prihvatljiva sol.
11. Spoj predstavljen s formulom III:
[image]
naznačen time što:
R1 je odabran iz skupine koju čine C1-C6 alkil, C3-C6 cikloalkil, -CH2CF3, i 4-6 člani heterociklički prsten;
R2 je odabran iz skupine koju čine H, halogen, hidroksi, C1-C3 alkil, C3-C4 cikloalkil i C4 heterociklički prsten;
kada n nije 0, R3 su isti ili različiti, i neovisno su odabrani iz skupine koju čine H, halogen, C1-C6 alkil i C1-C3 alkoksi po izboru supstituiran s najmanje jednim halogenom;
n je 0-3;
kada m nije zero, R4 su isti ili različiti i neovisno su odabrani iz skupine koju čine H, halogen, C1-C6 alkil, i OR11, pri čemu R11 je odabran iz skupine koju čine C3-C6 cikloalkil, C1-C6 alkil, aril, heteroaril i 4-6 člani heterociklički prsten;
m je 0-5;
kada p nije 0, R5 su isti ili različiti i neovisno su odabrani iz skupine koju čine H, halogen, C1-C4 alkil, C1-C4 alkoksi, C3-C4 cikloalkil, C3-C6 cikloalkoksi i C4 heterocikal;
p je 0-3;
q je 1-2;
R8 i R10 su isti ili različiti i neovisno su odabrani iz skupine koju čine halogen, H i C1-C3 alkil;
R9 je odabran iz skupine koju čine H, C1-C6 alkil i C3-C6 cikloalkil;
Y je odabran iz skupine koju čine -S(O)2R6, -S(O)2NR6R7, -C(O)NR6R7, -C(O)R6, -C(O)OR6, -CN; ili pri čemu Y i R10 oba predstavljaju -CF3;
R6 i R7 su isti ili različiti i neovisno su odabrani iz skupine koju čine H, C1-C6 alkil, C3-C6 cikloalkil, aril, heteroaril i 4-6 člani heterociklički prsten pri čemu navedeni alkil je zasićen ili nezasićen ili pri čemu R6 i R7 tvore 4-6 člani heterociklički prsten s N na koji su oni vezani, koji po izboru također sadrži kisikov atom;
R12 je odabran iz skupine koju čine H, C3-C4 cikloalkil i C1-C6 alkil; i
pri čemu bilo koji dio koji sadrži ugljik iz R1-R12 može biti po izboru supstituiran s jednim ili više halogenih atoma, fluorometanom, difluorometanom ili trifluorometanom, ili -OH;
ili njegove farmaceutski prihvatljive soli.
12. Spoj prema patentnom zahtjevu 11, naznačen time što R1 je odabran iz skupine koju čine C1-C6 alkil, C3-C6 cikloalkil, i 4-6 člani heterociklički prsten
R2 je odabran iz skupine koju čine H, halogen, metil i etil;
R3 su isti ili različiti, i neovisno su odabrani iz skupine koju čine H, halogen, metil i etil;
R4 su isti ili različiti i neovisno su odabrani iz skupine koju čine H, halogen, C1-C6 alkil i C1-C6 alkoksi;
R5 su isti ili različiti i neovisno su odabrani iz skupine koju čine H, halogen, metil i etil;
R8 i R10 su isti ili različiti i neovisno su odabrani iz skupine koju čine H i metil;
R9 je odabran iz skupine koju čine H, metil i etil; i
R6 i R7 su isti ili različiti i neovisno su odabrani iz skupine koju čine H i C1-C6 alkil ili pri čemu R6 i R7 tvore 4-6 atom heterociklički prsten s N na koji su oni vezani, koji po izboru također sadrži kisikov atom.
13. Spoj prema patentnom zahtjevu 11, naznačen time što R1 je -CH2CF3.
14. Spoj prema jednom od patentnih zahtjeva 11-13, naznačen time što Y je -C(O)NR6R7; R6 i R7 su metil; i R8 i Rio su oba H.
15. Spoj prema bilo kojem od patentnih zahtjeva 11-14, naznačen time što R1 je etil ili ciklobutil; ili pri čemu R9 je H.
16. Spoj prema bilo kojem od patentnih zahtjeva 11-15, naznačen time što R2 je F ili H.
17. Spoj prema bilo kojem od patentnih zahtjeva 11-16,
pri čemu m je 2, i jedan od R4 je F i drugi R4 je Cl; ili
pri čemu m je 2 i oba R4 su F; ili pri čemu m je 0.
18. Spoj prema bilo kojem od patentnih zahtjeva 11-17, naznačen time što n je 1 i R3 je F; ili pri čemu n je 0.
19. Spoj prema bilo kojem od patentnih zahtjeva 11-18, naznačen time što p je 1 i R5 je F; ili pri čemu p je 0.
20. Spoj prema patentnom zahtjevu 11, naznačen time što R1 je ciklobutil, etil ili -CH2CF3; R2 je H ili F; n je 0; m je 0 ili 2, i kada m je 2, tada jedan R4 je Cl i drugi R4 je F; p je 0; Y je - C(O)N(CH3)2; i R8, R9, R10 i R12 su svi -H.
21. Spoj prema patentnom zahtjevu 11 naznačen time što ima slijedeću formulu:
[image]
ili njegova farmaceutski prihvatljiva sol.
22. Spoj prema patentnom zahtjevu 1 ili zahtjevu 11, naznačen time što se bira iz skupine koja sadrži
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi) etil) amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3-fluor-1H-indazol-5-il)-2-fenil but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3-fluor-1H-indazol-5-il)-2-(3-fluor-5-(trifluormetil) fenil)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(4-fluor-1H-indazol-5-il)-2-fenil but-1-en-1-il) fenoksi) etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(3,5-difluorfenil)-1-(1H-indazol-5-il)but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(3,4-difluorfenil)-1-(1H-indazol-5-il)but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(3-klor-5-fluorfenil)-1-(1H-indazol-5-il)but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi) etil) amino)-N-metil-N-(prop-2-in-1-il)but-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil) amino)-N-(but-3-in-1-il)-N-metilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil) amino)-1-(azetidin-1-il)but-2-en-1-on;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil) amino)-1-(pirolidin-1-il)but-2-en-1-on;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil) amino)-1-(piperidin-1-il)but-2-en-1-on;
(E)-4-((2-(4-((E)-2-ciklobutil-1-(1H-indazol-5-il)-2-fenilvinil)fenoksi) etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-ciklobutil-1-(3-fluor-1H-indazol-5-il)-2-fenilvinil) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid 2,2,2-trifluor acetat;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil) amino)-1-morfolinobut-2-en-1-on;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en- 1-il)fenoksi)etil) amino)-N-etil-N-metilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en- 1-il)fenoksi)etil) amino)-N-metil-N-propilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N-(2-hidroksietil)-N-metilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-klor-4-fluorfenil)-1-(3- fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil) amino)-N,N,3-trimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-ciklobutil-1-(1H-indazol-5-il)-2- fenilvinil)fenoksi) etil)amino)-1-morfolinobut-2-en-1-on;
(E)-4-((2-(4-((E)-2-ciklobutil-1-(4-fluor-1H-indazol-5-il)-2-fenilvinil) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-((5-((Z)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)piridin-2-il) oksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-(o-tolil)but-1-en- 1-il)fenoksi) etil)amino)-N-(2-hidroksietil)-N-metilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-klor-4-fluorfenil)-1-(3-fluor- 1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N-(2-hidroksietil)-N-metilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-(4-izopropil fenil)but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-4-klor-1-(1H-indazol-5-il)-2-fenil but-1-en-1-il)fenoksi) etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-(4-izopropil fenil)but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-(difluormetoksi)fenil)-1-(1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-(2-(trifluormetoksi)fenil)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-(2-izopropil fenil)but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-etilfenil)-1-(1H-indazol-5-il) but-1-en-1-il)fenoksi) etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-(o-tolil)but-1- en-1-il)fenoksi)etil) amino)-N,N-dimetilbut-2-enamid;
(E)-1-(azetidin-1-il)-4-((2-(4-((E)-2-ciklobutil-1-(1H-indazol-5-il)-2-fenilvinil) fenoksi)etil)amino)but-2-en-1-on;
(E)-1-(azetidin-1-il)-4-((2-(4-((E)-2-ciklobutil-1-(3-fluor-1H-indazol-5-il)-2-fenilvinil)fenoksi)etil)amino)but-2-en-1-on;
(E)-4-((2-(4-((E)-2-ciklobutil-1-(1H-indazol-5-il)-2- fenilvinil) fenoksi) etil)amino)-N-(2-hidroksietil)-N-metilbut-2-enamid;
(E)-1-(azetidin-1-il)-4-((2-(4-((E)-2-ciklobutil-1-(1H-indazol-5-il)-2-(o-tolil) vinil)fenoksi)etil)amino)but-2-en-1-on;
(E)-4-((2-(4-((E)-1-(3-fluor-1H-indazol-5-il)-2-(2-fluor fenil)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3-fluor-1H-indazol-5-il)-2-(3-fluor fenil)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3-fluor-1H-indazol-5-il)-2-(3-fluorfenil)but-1-en-1-il) fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-klor-4-fluorfenil)-2-ciklobutil-1-(3-fluor-1H-indazol-5-il)vinil)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(2-fluor-4-((Z)-1-(3-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2,6-difluorfenil)-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilprop-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-ciklopropil-1-(1H-indazol-5-il)-2-fenilvinil)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-klor-4-fluorfenil)-1-(4-fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-((5-((Z)-2-(2-klor-4-fluorfenil)-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)piridin-2-il)oksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-((5-((Z)-2-(2-klor-4-fluorfenil)-4,4,4- trifluor-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)piridin-2-il)oksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-N,N-dimetil-4-((2-((5-((Z)-4,4,4-trifluor-1-(3-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)piridin-2-il)oksi)etil)amino)but-2-enamid;
(E)-4-((2-(3-fluor-4-((Z)-1-(3-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2,4-difluorfenil)-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3,6-difluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-((5-((Z)-1-(3-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)piridin-2-il)oksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-N,N-dimetil-4-((2-(4-((E)-4,4,4-trifluor-1-(3-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)but-2-enamid;
(E)-4-((2-((5-((Z)-2-ciklobutil-1-(3-fluor-1H-indazol-5-il)-2-fenilvinil)piridin-2-il)oksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-klorfenil)-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2-klor-4-fluorfenil)-1-(1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(7-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3-fluor-1H-indazol-5-il)-2-fenilpent-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3,7-difluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-2-(2,5-difluorfenil)-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(3-fluor-1H-indazol-5-il)-3-metil-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-5-((2-(4-((E)-4-fluor-1-(3-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilpent-2-enamid;
(E)-5-((2-(4-((E)-2-(2-klor-4-fluorfenil)-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilpent-2-enamid;
(E)-4-((2-(4-((E)-2-(2-klor-4-fluorfenil)-4,4,4-trifluor-1-(3-fluor-1H-indazol-5-il)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-(fenil-d5)but-1-en-1-il)fenoksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)propil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((1-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)propan-2-il)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-((6-((Z)-1-(3-fluor-1H-indazol-5-il)-2-fenilbut-1-en-1-il)piridin-3-il)oksi)etil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((3-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)propil)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((3-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)butan-2-il)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((1-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)-2-metilpropan-2-il)amino)-N,N-dimetilbut-2-enamid;
(E)-4-((2-(4-((E)-1-(1H-indazol-5-il)-2-fenilbut-1-en-1-il)fenoksi)-2-metilpropil)amino)-N,N-dimetilbut-2-enamid;
i (E)-4-((2-(4-((E)-2-ciklobutil-1-(3-fluor-1H-indazol-5-il)-2-fenilvinil)fenoksi)etil)amino)-N-(2-hidroksietil)-N-metilbut-2-enamid,
ili njihove farmaceutski prihvatljive soli.
23. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od patentnih zahtjeva 1-22, naznačen time što je uporabu u liječenju raka dojke.
24. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu s patentnim zahtjevom 23, naznačen time što je navedeni rak dojke ER-pozitivan rak dojke.
25. Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu s patentnim zahtjevom 24, naznačen time što navedeni ER-pozitivni rak dojke eksprimira mutirani protein ER-α.
26. Farmaceutski pripravak, naznačen time što sadrži spoj ili farmaceutski prihvatljivu sol prema bilo kojem od od zahtjeva 1 do 22 i farmaceutski prihvatljivu pomoćnu tvar.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562168581P | 2015-05-29 | 2015-05-29 | |
US201562168529P | 2015-05-29 | 2015-05-29 | |
US201562269745P | 2015-12-18 | 2015-12-18 | |
PCT/US2016/034782 WO2016196346A1 (en) | 2015-05-29 | 2016-05-27 | Tetrasubstituted alkene compounds and their use |
EP16804153.1A EP3302471B1 (en) | 2015-05-29 | 2016-05-27 | Tetrasubstituted alkene compounds and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211542T1 true HRP20211542T1 (hr) | 2022-01-07 |
Family
ID=57398096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211542TT HRP20211542T1 (hr) | 2015-05-29 | 2016-05-27 | Tetrasupstituirani spojevi alkena i njihova uporaba |
Country Status (33)
Country | Link |
---|---|
US (2) | US9796683B2 (hr) |
EP (2) | EP3981766A1 (hr) |
JP (1) | JP6325760B1 (hr) |
KR (1) | KR102664618B1 (hr) |
CN (2) | CN107847498B (hr) |
AU (1) | AU2016271126B2 (hr) |
BR (1) | BR112017025546B1 (hr) |
CA (1) | CA2987321C (hr) |
CL (1) | CL2017002996A1 (hr) |
CO (1) | CO2017013432A2 (hr) |
CY (1) | CY1125068T1 (hr) |
DK (1) | DK3302471T3 (hr) |
ES (1) | ES2895511T3 (hr) |
HR (1) | HRP20211542T1 (hr) |
HU (1) | HUE056199T2 (hr) |
IL (1) | IL255765B2 (hr) |
JO (1) | JO3735B1 (hr) |
LT (1) | LT3302471T (hr) |
MA (1) | MA43364B1 (hr) |
MD (1) | MD3302471T2 (hr) |
MX (1) | MX2017015226A (hr) |
MY (1) | MY186977A (hr) |
PE (1) | PE20181083A1 (hr) |
PH (1) | PH12017502142A1 (hr) |
PL (1) | PL3302471T3 (hr) |
PT (1) | PT3302471T (hr) |
RS (1) | RS62481B1 (hr) |
RU (1) | RU2733741C2 (hr) |
SI (1) | SI3302471T1 (hr) |
TW (1) | TWI704137B (hr) |
UA (1) | UA120882C2 (hr) |
WO (2) | WO2016196337A1 (hr) |
ZA (1) | ZA201707912B (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI704137B (zh) | 2015-05-29 | 2020-09-11 | 日商衛材R&D企管股份有限公司 | 四取代烯化合物及其等之用途 |
JP2019535778A (ja) * | 2016-11-24 | 2019-12-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 四置換アルケン化合物及び乳がんを治療するためのその使用 |
MA46896A (fr) * | 2016-11-24 | 2019-10-02 | Eisai R&D Man Co Ltd | Composés d'alcène tétrasubstitués et leur utilisation |
EP3544967B1 (en) * | 2016-11-28 | 2023-06-28 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
KR102517650B1 (ko) * | 2017-03-16 | 2023-04-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 유방암의 치료를 위한 조합물 요법 |
WO2019225552A1 (en) * | 2018-05-22 | 2019-11-28 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
KR20210105384A (ko) * | 2018-12-17 | 2021-08-26 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 에스트로겐 수용체 길항제 |
AU2020274113A1 (en) | 2019-05-14 | 2021-11-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
KR20220012891A (ko) | 2019-05-24 | 2022-02-04 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에스트로겐 수용체-알파 억제제의 경구 투여 형태로 암을 치료하는 방법 |
MX2021015486A (es) | 2019-06-19 | 2022-01-24 | Jiangsu Hengrui Medicine Co | Derivado de indazol, metodo de preparacion y aplicacion farmaceutica del mismo. |
CN110452177A (zh) * | 2019-09-02 | 2019-11-15 | 南通大学 | 一种5-溴-4-氟-1h-吲唑的合成方法 |
WO2021097046A1 (en) | 2019-11-13 | 2021-05-20 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2022001971A1 (zh) | 2020-06-28 | 2022-01-06 | 南京明德新药研发有限公司 | 并环吲唑类化合物 |
WO2022098953A1 (en) | 2020-11-06 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Method of treating breast cancer |
CN114644616B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
CN114644615B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的结晶形式及其制备方法 |
TW202241879A (zh) * | 2020-12-18 | 2022-11-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法 |
CA3214408A1 (en) | 2021-03-23 | 2022-09-29 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2023272410A1 (zh) * | 2021-06-27 | 2023-01-05 | 北京盛诺基医药科技股份有限公司 | 一种ERα受体共价结合拮抗剂 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3907290A1 (de) | 1989-03-07 | 1990-09-13 | Gerhard Prof Dr Eisenbrand | Steroidhormonrezeptoraffine antitumorwirkstoffe |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
US8063249B1 (en) * | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
US8785501B2 (en) | 2009-10-13 | 2014-07-22 | Duquesne University Of The Holy Spirit | Anti-cancer tamoxifen-melatonin hybrid ligand |
WO2011129837A1 (en) | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
NZ630124A (en) | 2012-03-20 | 2016-01-29 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
MX2015017655A (es) | 2013-06-19 | 2016-04-15 | Seragon Pharmaceuticals Inc | Modulador de receptores de estrogeno y uso del mismo. |
CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
EP3116497A2 (en) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Therapeutic combinations with estrogen receptor modulators |
WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
JP6807841B2 (ja) | 2014-12-18 | 2021-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーター及びその使用 |
TWI704137B (zh) | 2015-05-29 | 2020-09-11 | 日商衛材R&D企管股份有限公司 | 四取代烯化合物及其等之用途 |
-
2016
- 2016-05-27 TW TW105116750A patent/TWI704137B/zh active
- 2016-05-27 DK DK16804153.1T patent/DK3302471T3/da active
- 2016-05-27 IL IL255765A patent/IL255765B2/en unknown
- 2016-05-27 ES ES16804153T patent/ES2895511T3/es active Active
- 2016-05-27 HR HRP20211542TT patent/HRP20211542T1/hr unknown
- 2016-05-27 UA UAA201712962A patent/UA120882C2/uk unknown
- 2016-05-27 KR KR1020177037820A patent/KR102664618B1/ko active IP Right Grant
- 2016-05-27 LT LTEPPCT/US2016/034782T patent/LT3302471T/lt unknown
- 2016-05-27 MD MDE20180368T patent/MD3302471T2/ro unknown
- 2016-05-27 EP EP21191181.3A patent/EP3981766A1/en not_active Withdrawn
- 2016-05-27 PE PE2017002481A patent/PE20181083A1/es unknown
- 2016-05-27 PT PT168041531T patent/PT3302471T/pt unknown
- 2016-05-27 PL PL16804153T patent/PL3302471T3/pl unknown
- 2016-05-27 BR BR112017025546-4A patent/BR112017025546B1/pt active IP Right Grant
- 2016-05-27 CN CN201680043755.7A patent/CN107847498B/zh active Active
- 2016-05-27 WO PCT/US2016/034764 patent/WO2016196337A1/en active Application Filing
- 2016-05-27 SI SI201631340T patent/SI3302471T1/sl unknown
- 2016-05-27 AU AU2016271126A patent/AU2016271126B2/en active Active
- 2016-05-27 MY MYPI2017001740A patent/MY186977A/en unknown
- 2016-05-27 WO PCT/US2016/034782 patent/WO2016196346A1/en active Application Filing
- 2016-05-27 CA CA2987321A patent/CA2987321C/en active Active
- 2016-05-27 RS RS20211306A patent/RS62481B1/sr unknown
- 2016-05-27 HU HUE16804153A patent/HUE056199T2/hu unknown
- 2016-05-27 JP JP2017560920A patent/JP6325760B1/ja active Active
- 2016-05-27 RU RU2017146408A patent/RU2733741C2/ru active
- 2016-05-27 MA MA43364A patent/MA43364B1/fr unknown
- 2016-05-27 CN CN202110301494.7A patent/CN113024466A/zh active Pending
- 2016-05-27 US US15/167,373 patent/US9796683B2/en active Active
- 2016-05-27 EP EP16804153.1A patent/EP3302471B1/en active Active
- 2016-05-27 MX MX2017015226A patent/MX2017015226A/es unknown
- 2016-05-29 JO JOP/2016/0102A patent/JO3735B1/ar active
-
2017
- 2017-09-22 US US15/713,107 patent/US10851065B2/en active Active
- 2017-11-21 ZA ZA2017/07912A patent/ZA201707912B/en unknown
- 2017-11-24 PH PH12017502142A patent/PH12017502142A1/en unknown
- 2017-11-27 CL CL2017002996A patent/CL2017002996A1/es unknown
- 2017-12-27 CO CONC2017/0013432A patent/CO2017013432A2/es unknown
-
2021
- 2021-11-08 CY CY20211100961T patent/CY1125068T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211542T1 (hr) | Tetrasupstituirani spojevi alkena i njihova uporaba | |
HRP20211708T1 (hr) | Antagonisti lpa | |
HRP20171961T1 (hr) | Kemijski spojevi | |
HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
HRP20190815T1 (hr) | Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret) | |
HRP20210928T1 (hr) | Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola | |
HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
HRP20210320T1 (hr) | Spojevi heteroarila za liječenje oftalmičkih bolesti | |
PE20220253A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
RU2018104310A (ru) | Азотсодержащие гетероциклы в качестве пестицидов | |
JP2017505790A5 (hr) | ||
JP2016535772A5 (hr) | ||
HRP20161547T1 (hr) | Derivati 5-fluor-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku skupinu | |
JP2015531366A5 (hr) | ||
PE20141064A1 (es) | Compuestos de ester boronato y composciones farmaceuticas de los mismos | |
NZ607638A (en) | Novel compounds and compositions for the inhibition of nampt | |
AR084174A1 (es) | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica | |
IL273000B2 (en) | Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1) | |
EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
IN2014CN03268A (hr) | ||
JP2017517565A5 (hr) | ||
HRP20230233T1 (hr) | Inhibitori pirazola magl |